A Single Arm, Uni-Center, Prospective Clinical Investigation to Evaluate Safety and Efficacy of the WaisFix100i for Intracapsular Femoral Fracture Fixation
Trial Snapshot
- Phase
- Not Applicable
- Status
- Suspended
- Sponsor
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- The safety endpoint is measure by paucity incidence of treatment related major complications.
Study Overview
Brief Summary
The purpose of this study is to determine the safety and efficacy of using WaisFix100i device for Intracapsular Femoral Fracture Fixation.
Detailed Description
Fractures of the neck of the femur represent an estimated cost to society that exceeds ten billion dollars annually in the USA only.
Fractures have been treated with immobilization, traction, amputation, and internal fixation throughout history. Immobilization by casting, bracing, or splinting a joint above and below the fracture was used for most long bone fractures.
Several studies have suggested that reduction and fixation of an Intracapsular fracture of the hip with multiple pins or screws is associated with a lower rate of morbidity and mortality than treatment with prosthetic replacement. With improved methods of fixation and a tendency toward earlier weight-bearing, internal fixation is believed to be a better mode of treatment for younger, more active patients.
On the other hand, the internal fixation procedure may result with number of possibilities for serious complications and biomechanical disadvantages, leading to the device failure. This led to a growing tendency to prefer total or partial hip replacement as the common treatment for intracapsular fracture, although the internal fixation is the favorable procedure in the professional literature.
OrthoMediTec has developed the WaisFix100i device, a new concept for Intracapsular Femoral Fracture Fixation and bone grafting using minimally invasive procedures. The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 50 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male/Female with Intracapsular femoral fracture type Garden I-II and several III.
- •Subject able to comprehend and give informed consent for participation in this study.
Exclusion Criteria
- •Known active infectious disease.
- •Terminal diseases
- •Patients in high risk and/or acute cardio-vascular disease.
- •Known cognitive disorder, psychiatric and/or neurological disease
- •Physician objection.
- •Age under 50 or above
- •Concurrent participation in any other clinical study
- •Patients cannot understand or not willing to sign the informed consent.
Outcomes
Primary Outcomes
The safety endpoint is measure by paucity incidence of treatment related major complications.
Time Frame: Study duration
Secondary Outcomes
- Efficacy endpoint is measure by the following: 1. A subject is scored a success if he had no revision surgery, hemi- arthroplasty or total hip replacement surgery by 12 months; 2. Time to functional recovery(Study duration)
